Palvella Therapeutics, Inc. (PVLA)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$157.24+1.14%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
QuarterlyIQ Insights · PVLA
Income statement, balance sheet, and cash flow — annual and quarterly history, as reported.
Figures in millions of USD, except per-share and ratios.
| TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 | Dec 2015 | Dec 2014 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenues | |||||||||||||
| Revenues | — | — | — | 42.8 | 25.9 | 31.4 | 29.3 | 46.3 | 29.1 | 25.3 | 5.8 | 2.9 | 5.4 |
| Total Revenues | — | — | — | 42.8 | 25.9 | 31.4 | 29.3 | 46.3 | 29.1 | 25.3 | 5.8 | 2.9 | 5.4 |
| Operating Expenses & Income | |||||||||||||
| R&D Expenses | 35.5 | 22.8 | 8.2 | 8.8 | 53.0 | 66.7 | 46.5 | 55.0 | 41.5 | 22.3 | 19.7 | 8.2 | 5.6 |
| Operating Income | (57.7) | (38.6) | (14.1) | (11.9) | (43.5) | (51.8) | (33.9) | (27.2) | (30.8) | (14.6) | (22.8) | (13.7) | (7.2) |
| Earnings from Continuing Operations | |||||||||||||
| Interest Expense | — | — | — | — | — | — | — | — | — | — | — | — | 2.7 |
| Other Non-Operating Income / Expenses | — | — | — | — | — | — | — | — | — | — | — | — | (2.7) |
| Asset Writedown | — | — | — | 13.9 | 0.0 | — | — | — | — | — | — | — | — |
| EBT, Incl. Unusual Items | (61.7) | (41.7) | (17.4) | 18.7 | (33.3) | (45.7) | (37.1) | (25.5) | (27.1) | (16.5) | (22.6) | (13.9) | (9.8) |
| Income Tax Expense | — | — | — | 0.0 | 0.0 | 0.0 | 0.2 | 0.0 | (0.3) | 1.1 | 0.2 | 0.2 | (0.0) |
| Net Income | |||||||||||||
| Net Income | (61.7) | (41.7) | (17.4) | 18.7 | (33.3) | (45.7) | (37.2) | (25.5) | (26.8) | (17.6) | (22.8) | (14.1) | (9.8) |
| Per Share | |||||||||||||
| Basic EPS | (4.30) | (3.71) | (7.83) | 2.19 | (0.45) | (0.71) | (0.68) | — | — | — | — | — | — |
| Diluted EPS | (4.30) | (3.71) | (7.83) | 2.17 | — | (0.71) | (0.68) | — | — | — | — | — | — |
| Basic Weighted Avg Shares | 14.4 | 11.3 | 2.2 | 1.8 | 74.2 | 64.5 | 54.5 | — | — | — | — | — | 6.1 |
| Diluted Weighted Avg Shares | 14.4 | 11.3 | 2.2 | 1.8 | — | 64.5 | 54.5 | — | — | — | — | — | — |
| Supplemental | |||||||||||||
| EBITDA | — | — | — | (10.0) | (40.7) | (49.4) | — | — | — | — | — | — | — |
| EBIT | (57.7) | (38.6) | (14.1) | (11.9) | (43.5) | (51.8) | (33.9) | (27.2) | (30.8) | (14.6) | (22.8) | (13.7) | (7.2) |
| Effective Tax Rate | — | — | — | 0.0% | 0.0% | 0.0% | -0.4% | 0.0% | 1.2% | -6.7% | -0.7% | -1.5% | 0.0% |
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.